In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated cyclophosphamide/ifosfamide, high-dose cytarabine and methotrexate, doxorubicin, etoposide, ...

BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

BeyondSpring Inc.’s BYSI share price has dipped by 10.67%, which has investors questioning if this is right time to buy.

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a first-line combination treatment for an aggressive form of lung cancer.

Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine , Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced ...